Bristol Myers Squibb (BMY) Revenue (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Revenue for 18 consecutive years, with $13.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 5.74% year-over-year to $13.0 billion in Q2 2026; TTM through Jun 2026 was $49.2 billion, a 3.11% increase from a year earlier, with the FY2025 full-year figure at $48.2 billion, changed 0.22% from the prior year.
• Revenue was $13.0 billion for Q2 2026 at Bristol Myers Squibb, up from $11.5 billion in the prior quarter.
• Over five years, Revenue peaked at $13.0 billion in Q2 2026 and troughed at $11.0 billion in Q3 2023.
• A 5-year average of $11.8 billion and a median of $11.8 billion in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue gained 8.69% in 2024 and declined 5.6% in 2025, its largest moves.
• Over 5 years, Revenue stood at $11.4 billion in 2022, then gained by 0.62% to $11.5 billion in 2023, then gained by 7.54% to $12.3 billion in 2024, then grew by 1.3% to $12.5 billion in 2025, then advanced by 3.77% to $13.0 billion in 2026.
• The last three Revenue figures came in at $13.0 billion (Q2 2026), $11.5 billion (Q1 2026), and $12.5 billion (Q4 2025), per Business Quant data.